These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 37600799)

  • 61. Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage non-small cell lung cancer: A National Cancer Database study.
    Wu J; Bai HX; Chan L; Su C; Zhang PJ; Yang L; Zhang Z
    J Thorac Cardiovasc Surg; 2020 Nov; 160(5):1350-1357.e11. PubMed ID: 32033815
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Neoadjuvant immunotherapy for resectable non-small cell lung cancer.
    Xie H; Shi X; Wang G
    Am J Cancer Res; 2021; 11(6):2521-2536. PubMed ID: 34249414
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Surgical Outcomes for Early Stage Non-small Cell Lung Cancer at Facilities With Stereotactic Body Radiation Therapy Programs.
    Syed YA; Stokes W; Rupji M; Liu Y; Khullar O; Sebastian N; Higgins K; Bradley JD; Curran WJ; Ramalingam S; Taylor J; Sancheti M; Fernandez F; Moghanaki D
    Chest; 2022 Mar; 161(3):833-844. PubMed ID: 34785235
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review.
    Turchan WT; Chmura SJ
    Ann Palliat Med; 2021 May; 10(5):6028-6044. PubMed ID: 33440982
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Jia XH; Xu H; Geng LY; Jiao M; Wang WJ; Jiang LL; Guo H
    Lung Cancer; 2020 Sep; 147():143-153. PubMed ID: 32717571
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
    Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.
    Jiang L; Huang J; Jiang S; Rong W; Shen Y; Li C; Tian Y; Ning J; Chen X; Yang Y; Ding Z; Li Z; Luo Q
    Cancer Immunol Immunother; 2021 Aug; 70(8):2313-2321. PubMed ID: 33512555
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety.
    Shao L; Lou G
    J Thorac Dis; 2022 Sep; 14(9):3565-3574. PubMed ID: 36245597
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.
    Rusthoven KE; Hammerman SF; Kavanagh BD; Birtwhistle MJ; Stares M; Camidge DR
    Acta Oncol; 2009; 48(4):578-83. PubMed ID: 19373699
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial.
    Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I
    BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.
    Scotti V; Bruni A; Francolini G; Perna M; Vasilyeva P; Loi M; Simontacchi G; Viggiano D; Lanfranchi B; Gonfiotti A; Topulli J; Olmetto E; Maragna V; Ferrari K; Bonti V; Comin C; Balduzzi S; D'Amico R; Lohr F; Voltolini L; Livi L
    Clin Lung Cancer; 2019 Jan; 20(1):e53-e61. PubMed ID: 30348595
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
    Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
    J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Impact of immunotherapy on the therapeutic strategy for the management of stage I non-small cell lung cancer: The radiation oncologist's point of view].
    Khalifa J
    Cancer Radiother; 2023 Sep; 27(6-7):653-658. PubMed ID: 37573193
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison Between Stereotactic Radiotherapy and Sublobar Resection for Non-Small Cell Lung Cancer.
    Tamura M; Matsumoto I; Tanaka Y; Saito D; Yoshida S; Kakegawa S; Kumano T; Shimizu Y; Tamamura H; Takanaka T; Takemura H
    Ann Thorac Surg; 2019 May; 107(5):1544-1550. PubMed ID: 30458155
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
    Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
    J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: A National Cancer Data Base analysis.
    Nanda RH; Liu Y; Gillespie TW; Mikell JL; Ramalingam SS; Fernandez FG; Curran WJ; Lipscomb J; Higgins KA
    Cancer; 2015 Dec; 121(23):4222-30. PubMed ID: 26348268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.